Show simple item record

dc.creatorCasini, N
dc.creatorForte, IM
dc.creatorMastrogiovanni, G
dc.creatorPentimalli, F
dc.creatorAngelucci, A
dc.creatorFestuccia, C
dc.creatorTomei, V
dc.creatorCeccherini, E
dc.creatorDi Marzo, D
dc.creatorSchenone, S
dc.creatorBotta, M
dc.creatorGiordano, A
dc.creatorIndovina, P
dc.date.accessioned2021-01-29T22:21:17Z
dc.date.available2021-01-29T22:21:17Z
dc.date.issued2015-01-01
dc.identifier.issn1949-2553
dc.identifier.issn1949-2553
dc.identifier.doihttp://dx.doi.org/10.34944/dspace/5234
dc.identifier.other25762618 (pubmed)
dc.identifier.urihttp://hdl.handle.net/20.500.12613/5252
dc.description.abstractRecent data suggest that SRC family kinases (SFKs) could represent potential therapeutic targets for rhabdomyosarcoma (RMS), the most common soft-tissue sarcoma in children. Here, we assessed the effect of a recently developed selective SFK inhibitor (a pyrazolo[3,4-d]pyrimidine derivative, called SI221) on RMS cell lines. SI221, which showed to be mainly effective against the SFK member YES, significantly reduced cell viability and induced apoptosis, without affecting non-tumor cells, such as primary human skin fibroblasts and differentiated C2C12 cells. Moreover, SI221 decreased in vitro cell migration and invasion and reduced tumor growth in a RMS xenograft model. SFK inhibition also induced muscle differentiation in RMS cells by affecting the NOTCH3 receptor-p38 mitogen-activated protein kinase (MAPK) axis, which regulates the balance between proliferation and differentiation. Overall, our findings suggest that SFK inhibition, besides reducing RMS cell growth and invasive potential, could also represent a differentiation therapeutic strategy for RMS.
dc.format.extent12421-12435
dc.language.isoen
dc.relation.haspartOncotarget
dc.relation.isreferencedbyImpact Journals, LLC
dc.rightsCC BY
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/
dc.subjectRhabdomyosarcoma
dc.subjectSRC family inhibition
dc.subjectNOTCH3
dc.subjectmuscle differentiation
dc.subjectp38 MAPK
dc.subjectYES
dc.titleSRC family kinase (SFK) inhibition reduces rhabdomyosarcoma cell growth in vitro and in vivo and triggers p38 MAP kinase-mediated differentiation
dc.typeArticle
dc.type.genreJournal Article
dc.relation.doi10.18632/oncotarget.3043
dc.ada.noteFor Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu
dc.creator.orcidGiordano, Antonio|0000-0002-5959-016X
dc.date.updated2021-01-29T22:21:12Z
refterms.dateFOA2021-01-29T22:21:17Z


Files in this item

Thumbnail
Name:
SRC family kinase (SFK) inhibition ...
Size:
3.451Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

CC BY
Except where otherwise noted, this item's license is described as CC BY